115 related articles for article (PubMed ID: 24530340)
21. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
[TBL] [Abstract][Full Text] [Related]
22. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
24. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Piironen T; Laursen B; Pass J; List K; Gårdsvoll H; Ploug M; Danø K; Høyer-Hansen G
Clin Chem; 2004 Nov; 50(11):2059-68. PubMed ID: 15345662
[TBL] [Abstract][Full Text] [Related]
25. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
26. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
27. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
32. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
33. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS
Oncology; 2004; 66(3):210-7. PubMed ID: 15218312
[TBL] [Abstract][Full Text] [Related]
34. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
[TBL] [Abstract][Full Text] [Related]
35. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
36. Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma.
Alpízar-Alpízar W; Christensen IJ; Santoni-Rugiu E; Skarstein A; Ovrebo K; Illemann M; Laerum OD
Int J Cancer; 2012 Aug; 131(4):E329-36. PubMed ID: 21901747
[TBL] [Abstract][Full Text] [Related]
37. Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
Thurison T; Almholt K; Gårdsvoll H; Ploug M; Høyer-Hansen G; Lund IK
Mol Carcinog; 2016 May; 55(5):717-31. PubMed ID: 25809119
[TBL] [Abstract][Full Text] [Related]
38. Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.
Kristensen G; Berg KD; Lippert S; Christensen IJ; Brasso K; Høyer-Hansen G; Røder MA
J Clin Pathol; 2017 Dec; 70(12):1063-1068. PubMed ID: 28607123
[TBL] [Abstract][Full Text] [Related]
39. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Lomholt AF; Høyer-Hansen G; Nielsen HJ; Christensen IJ
Br J Cancer; 2009 Sep; 101(6):992-7. PubMed ID: 19672256
[TBL] [Abstract][Full Text] [Related]
40. [Effect of vacuum-assisted closure on the expression of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in acute and chronic wounds healing].
Li YJ; Cao DY; Chen SZ
Zhonghua Zheng Xing Wai Ke Za Zhi; 2006 Jul; 22(4):306-9. PubMed ID: 17017150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
